Abstract
BackgroundA number of anti-cancer monoclonal antibodies (mAbs), including the anti-CD20 mAb rituximab, are thought to mediate their antitumor effect, in large part, through NK cell Antibody-Dependent Cellular Cytotoxicity (ADCC). These...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
